Matthew Biegler
Stock Analyst at Oppenheimer
(1.04)
# 3,621
Out of 4,761 analysts
77
Total ratings
26.47%
Success rate
-12.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $109.95 | +4.59% | 1 | Dec 10, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $50 → $40 | $17.77 | +125.10% | 3 | Oct 31, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $21.85 | +142.56% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $13.17 | +150.57% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $2.32 | +762.07% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $3.92 | - | 6 | Sep 10, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $17 → $15 | $7.68 | +95.31% | 4 | Aug 13, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $2.17 | +406.91% | 1 | Aug 8, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 | $4.99 | +501.20% | 4 | Aug 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Outperform | $114 → $125 | $92.25 | +35.50% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $19.24 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $3.85 | +263.64% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 → $10 | $1.37 | +629.93% | 6 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.54 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.42 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $12.43 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $15 | $0.16 | +9,153.55% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.54 | +351.26% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.05 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.68 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $4.57 | +7,777.46% | 1 | Nov 30, 2022 |
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $109.95
Upside: +4.59%
Arvinas
Oct 31, 2024
Maintains: Outperform
Price Target: $50 → $40
Current: $17.77
Upside: +125.10%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $21.85
Upside: +142.56%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $13.17
Upside: +150.57%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.32
Upside: +762.07%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.92
Upside: -
ORIC Pharmaceuticals
Aug 13, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $7.68
Upside: +95.31%
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $2.17
Upside: +406.91%
Olema Pharmaceuticals
Aug 7, 2024
Reiterates: Outperform
Price Target: $30
Current: $4.99
Upside: +501.20%
Blueprint Medicines
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $92.25
Upside: +35.50%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $19.24
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $3.85
Upside: +263.64%
May 13, 2024
Reiterates: Outperform
Price Target: $15 → $10
Current: $1.37
Upside: +629.93%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.54
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.42
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $12.43
Upside: -
Aug 11, 2023
Maintains: Outperform
Price Target: $50 → $15
Current: $0.16
Upside: +9,153.55%
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $5.54
Upside: +351.26%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.05
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.68
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $4.57
Upside: +7,777.46%